CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months and year ended December 31, 2015, and provided an update of recent corporate developments.
“2015 marked a year of significant achievements for Sarepta, the most important being the filing of our New Drug Application for eteplirsen,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. “2016 will be a pivotal year for the company as we prepare for an FDA advisory committee meeting and May 26th PDUFA date for eteplirsen.”
